drugset / Trial / NCT01637285

A Pharmacokinetic Study of CVX-096 (PF-04856883) in Healthy Volunteers

NCT01637285 ↗

Phase 1 Completed 49 enrolled Pfizer
RandomizedParallel-groupOpen-label

Summary

The purpose of the study is to further evaluate the PK characteristics of PF-04856883.

Timeline

Start
2012-08
Primary completion
2013-01
Completion
2013-01

Drugs

EvaluationDrugModalityDoseRoute
Subject PF-04856883 Unknown — Subcutaneous

Indications

No indication recorded.